Novo Nordisk presented CagriSema EASD 2026 data showing changed brain responses to food cues, reduced ‘food noise’, less fat around abdominal organs and preliminary bone reassurance in adults with obesity or type 2 diabetes.
Novo Nordisk will present 52 abstracts at the European Congress on Obesity, showcasing a portfolio that includes high-dose Wegovy and new data on women’s health during menopause.
Novo Nordisk has officially submitted a New Drug Application to the FDA for CagriSema, a first-of-its-class once-weekly injection for chronic weight management. Combining semaglutide with a novel amylin analogue, clinical data from the REDEFINE program shows the treatment can achieve over 20% weight loss in adults with obesity.
Novo Nordisk keeps pushing the boundaries of obesity innovation by revealing the whole Phase 3 REDEFINE 1 and 2 trial data, which shed light on CagriSema’s revolutionary potential.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
